Rein Therapeutics Inc.

NASDAQ: RNTX · Healthcare · Medical - Pharmaceuticals

PublicHQ Austin, TX · TravisCIK 0001420565Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

36D

FH 26DQ 50GM —SS 42

v0.1 · 55/100 weight · provisional

↑ disclosure history, balance-sheet leverage · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$49.9M

Employees

Market cap

$27.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$49.9M-$49.9M2025

Operating income-$50.6M-$50.6M2025

Total assets$24.2M$24.2M2025

Liabilities$7.2M$7.2M2025

Equity$16.9M$16.9M2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Rein Therapeutics Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Harvard Bioscience, Inc.58C Telescope Innovations Corp.——SCYNEXIS, Inc.61C Cryo-Cell International, Inc.63C

Neighbors

Travis →

Tesla, Inc.$94.8B69B Oracle Corporation$67.4B85A CrowdStrike Holdings, Inc.$4.8B62C Digital Realty Trust, Inc.$6.1B68B SailPoint, Inc.$1.1B49D Cirrus Logic, Inc.$2.0B80B+

Key facts

CEOJames Brian Windsor

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersAustin, TX

ExchangeNASDAQ: RNTX

Employees11

IPO date2017-06-29

Latest filings

DEF 14A2026-06-08 10-Q2026-05-15 8-K2026-05-04 10-K2026-03-26 8-K2026-03-02 8-K2026-02-19 8-K2026-01-16 8-K2025-12-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.